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Abstract
A key event in chronic allergic asthma is the TGF-b-induced activation of fibroblasts into a-SMA-positive myofibroblasts
which synthesize type-I collagen. In the present study we investigated the effect of the anti-fibrotic molecule BMP-7 in
asthma. Balb/c mice were immunized i.p. with ovalbumin in alum and challenged every 2 days with ovalbumin aerosol (two
or six challenges for acute and chronic protocols, respectively). The lung was evaluated for: a-SMA and type-I collagen by
immunohistochemistry; BMP-7 and TGF- b1 gene expression by qRT-PCR; type-I collagen and Smads 2 and 3 by
immunoblotting; mucus by PSA staining. Type-I collagen around bronchi, a-SMA, mucus secretion, TGF- b1 and BMP-7 gene
expression were all increased in asthma. The TGF- b1/BMP-7 ratio was higher in the chronic group and correlated with
higher levels of collagen. Fibroblasts isolated from asthmatic and healthy lungs produced type-I collagen upon stimulation
with TGF- b1 via phosphorylation of Smad-2, Smad-3. Pre-treatment of the fibroblasts with BMP-7 reduced collagen
production and Smads phosphorylation. Intranasal treatment of asthmatic mice with recombinant BMP-7 during the
immunization protocol reduced lung inflammation and type I collagen deposition. These results suggest a protective role
for BMP-7 in lung allergic inflammation, opposing the pro-fibrotic effects of TGF- b1.
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Introduction
Allergic asthma is characterized by chronic inflammation of the
airways, bronchial hyper-responsiveness, and several structural
changes in the lung, collectively termed airway remodeling [1,2].
It is a Th2-mediated inflammation that involves infiltration of
effector T lymphocytes and eosinophils. Products of these cells’
activation and degranulation ultimately damage the parenchyma
and degrade the extracellular matrix (ECM) components. During
this injury, growth factors, which are primarily secreted in their
inactive form, bind to the ECM and are released by proteolysis
into their active form. TGF- b1 is one of these growth factors,
being a key mediator of fibrosis [3,4]. TGF- b1 induces the
differentiation of fibroblasts into myofibroblasts, which are the
effector cells in many fibrotic lung diseases, including asthma [5].
The myofibroblast is characterized by expression of a-SMA, and
by intensive synthesis of type I collagen, associated with increased
proliferation, all key events in wound healing [6,7]. Specifically in
asthma, the characteristic structural changes which occur in the
lung are: thickening of the bronchial smooth muscle wall, high
number of infiltrating cells, and deposition of an abnormal amount
of ECM components beneath the bronchial epithelium. These
alterations end up replacing the normal lung parenchyma by scar
tissue, diminishing the gas exchange surface and, consequently,
determining the decreased respiratory capacity of the patients.
Although it has already been established that fibrosis is due to an
imbalance in the regulation of the healing process, the elements
involved in this deregulation are still not well characterized.
Recently, much attention has been given to the capacity of the
tissue to counteract the injury through upregulation of the so-
called cytoprotective response. BMP-7, a member of the TGF-b
superfamily, was originally described as being involved in the
development and homeostasis of several tissues and organs [8].
Further studies showed that it is also involved in the regulation of a
wide spectrum of cell functions, such as proliferation, differenti-
ation, and apoptosis [9,10]. In renal disease, BMP-7 was shown to
act as an anti-fibrotic factor, counteracting the actions of TGF-b
[11]. TGF-b and BMP-7 signal through independent Smad
proteins [12,13].
In the present study, we investigated the role of these two
molecules in lung remodeling in murine asthma, and the
mechanisms underlying collagen production by isolated lung
fibroblasts.
Methods
Reagents
Grade V ovalbumin (OVA) was purchased from Sigma-Aldrich
(St. Louis, MO). Bovine serum albumin (BSA) was obtained from
US Biological (Swampscott, MA). Aluminum hydroxide (Rehy-
dragel HPA) was obtained from Reheis Inc. (Berkeley Heights,
NJ). Dulbecco’s modified Eagle’s medium (DMEM) and penicil-
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lin/streptomycin were obtained from Invitrogen (Carlsbad, CA).
Fetal bovine serum (FBS) was purchased from Gibco (Grand
Island, NY). TGF-b1 was purchased from Abcam (Cambridge,
UK) and the ELISA kit for TGF-b1 from eBioscience (San Diego,
CA). The rhBMP-7 used in the in vitro experiments was purchased
from Gibco (cat # PHC7204), while the rhBMP-7 used in the in
vivo experiments was a kind gift from Dr. Mari Sogayar from the
Institute of Chemistry, University of Sa˜o Paulo, Brazil [14]. The
biological activity of the rhBMP-7 used in our in vivo experiments
was tested in mouse C2C12 cells (ATCC CRL-1772), proving its
activity in mouse cells [14]. In addition, the biological activity of
the commercially available BMP-7 used in this work was also
tested in murine ADTC5 cells, as per product analysis sheet.
Enhanced chemiluminescence (ECL) reagent was obtained from
Thermo Scientific (Waltham, MA). Antibodies used for immuno-
blotting were as follows: anti-rabbit collagen I (AbCam, Cam-
bridge, MA.), anti-b-actin (Sigma-Aldrich). The anti-phospho-p38
MAPK and anti-p38 MAPK; anti-phospho-Smad2, anti-phospho-
Smad3 and anti-Smad2/3; anti-phospho-Erk 1/2 and anti-ErkK
were from Cell Signaling Technology, Beverly, MA. The
secondary antibodies used in developing the Western blots were
obtained from Sigma-Aldrich and Cell Signaling Technology.
Animals
Male Balb/c mice weighing 20–25 g, 6–8 weeks old, from our
own animal facilities were housed in a room with a 12 h light–dark
cycle with water and food ad libitum. Animal care and research
protocols were in accordance with the principles and guidelines
adopted by the Brazilian College of Animal Experimentation
(COBEA) and this project was approved by the Ethical Committee
for Animal Research of the Institute of Biomedical Sciences of the
University of Sa˜o Paulo.
Induction of allergic asthma
Mice were sensitized on days 0 and 7 by an intraperitoneal
injection of a mixture containing 50 mg of ovalbumin (OVA;
Grade V, Sigma, USA) and 1 mg of Al(OH)3 in PBS (a total
volume of 0.2 ml). Mice were challenged by exposure to an aerosol
of OVA generated by an ultrasonic nebulizer (ICEL US-800, SP,
Brazil) delivering particles of 0.5–10 mm diameter at approxi-
mately 0.75 cc/min for 20 min at days 12, 15, 19, 22, 26, and 29
(Figure 1). The concentration of OVA in the nebulizer was 2.5%
w/v in PBS. The control group consisted of animals immunized as
previously described and challenged two or six times with PBS
solution. The control animals received two immunizations with
OVA/Alum and six challenges with PBS.
Bronchoalveolar lavage
Animals were sacrificed by asphyxiation, 24 h after exposure to
the last aerosol challenge. A tracheal cannula was inserted via a
midcervical incision, and the airways were lavaged twice with 1 ml
of phosphate-buffered saline (PBS, pH 7.4 at 4uC).
Total and differential cell counts in the bronchoalveolar
lavage fluid
The bronchoalveolar lavage fluid was centrifuged at 1706g for
10 min at 4uC, the supernatant was removed, and the cell pellet
was re-suspended in 1 ml of PBS. One volume of a solution
containing 0.5% crystal violet dissolved in 30% acetic acid was
added to nine volumes of the cell suspension. The total number of
cells was determined by counting in a hematocytometer. Following
cytocentrifugation of the bronchoalveolar lavage fluid, cells were
stained with hematoxylin-eosin (Hema 3) for determination of the
cell numbers.
Histology
Lung tissue was harvested and fixed in a 10% buffered-formalin
solution and routinely processed for histological inclusion in
paraffin. Five-mm thick tissue sections were stained with Periodic
Acid of Schiff (PAS) for visualizing mucus and with Masson’s
Trichrome for visualizing collagen.
Immunohistochemistry
Tissue sections (5-mm thick) were deparaffinized, hydrated, and
submitted to antigenic retrieval by incubation in a 10 mM sodium
citrate buffer at 90uC for 20 minutes. Sections were treated with
3% H2O2 in PBS for 30 minutes to block endogenous peroxidase
activity. Non-specific staining was blocked by incubating the
sections for 30 minutes with 10% bovine serum albumin in PBS.
Primary antibodies were incubated overnight at 4uC in a
concentration of 1:200 in 0.3% Tween 20 in PBS. Sections were
thoroughly washed with PBS and then incubated with biotin-
conjugated goat anti-rabbit IgG (Vector, USA) for 1 hour at room
temperature. After washes in PBS, sections were incubated in
streptavidin-peroxidase ABC kit (Vector, USA) for 1 hour at room
temperature. Peroxidase was visualized using 0.03% 3,39-diami-
nobenzidine in PBS with 0.08% H2O2. Sections were counter-
stained with Mayer’s Hematoxylin, dehydrated in ethanol, and
mounted in VectaMount mounting medium (Vector, USA).
Morphometric analysis
Morphometric analysis was performed using a Nikon DXM
1200c digital camera, and Nikon NIS – Elements AR 2.30
software. The area of positivity was measured (in mm2) in the
maximal number of bronchioles per slide and the area of each
bronchiole was normalized by the average of three different
measurements of the diameter of the same bronchiole to rule out
the influence of the caliber of the bronchiole in the extent of
collagen deposition. Results are expressed as the mean of total
area/diameter for each animal, and as mean values 6 standard
Figure 1. Allergic asthma protocol. Mice were sensitized on days 0 and 7 by an intraperitoneal injection of a mixture containing 50 mg of
ovalbumin and 1 mg of Al(OH)3 in PBS. Mice were challenged by exposure to an aerosol of OVA for 20 min at days 12, 15, 19, 22, 26, and 29.
doi:10.1371/journal.pone.0095959.g001
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errors with comparisons between groups performed by analysis of
variance (ANOVA). P,0.05 was considered statistically signifi-
cant.
Determination of the concentration of TGF-b1 and BMP-7
TGF-b1 and BMP-7 were measured by ELISA in the BAL
supernatants according to the manufacturer’s instructions.
Real-time RT-PCR
Lung tissue was collected, washed in sterile PBS, and frozen in
liquid nitrogen, and then stored at 280uC. Total RNA was
extracted with Trizol Reagent (Invitrogen, USA) and the
concentration of RNA was determined by spectrophotometer
reading at absorbance 260 nm. cDNAs were synthesized by
reverse transcriptase MML-V (Promega, USA). Real-time PCR
Figure 2. In vivo treatment with rhBMP-7. Mice were anesthetized and human recombinant BMP-7 (300 mg/kg in a total volume of 30 ml) in
PBSA isotonic buffer (140 mM NaCl, 2,7 mM KCl, 8 mM Na2HPO4 and 1.5 mM KH2PO4), was administered intranasally every other day between days
17 and 30 of the chronic asthma protocol.
doi:10.1371/journal.pone.0095959.g002
Figure 3. Fibrosis markers in the asthmatic lung. Lung sections were taken from animals with asthma (6 challenges), stained with PAS for
mucus (A) or prepared for immunohistochemical and morphometric analysis of a-SMA (B) and collagen type I (C). Data are representative of 5 animals
in each of 3 independent experiments. Bars = 50 mm. *p,0.05 comparing with control group.
doi:10.1371/journal.pone.0095959.g003
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was performed using the semi-quantitative SYBR Green assay
(Applied Biosystem, USA) using specific primers for collagen I,
BMP-7, and TGF-b1, and HPRT as the housekeeping gene.
Primers were designed according to the RNA sequence published
on GenBank. Primer sequences were as follows: BMP-7 sense:
TTT GAC ATC ACA GCC ACC AGC AAC, anti-sense: ATG
AAC CTC CGT GGC CTT GAA GAA; Collagen I sense: TGG
CCA AGA AGA CAT CCC TGA AGT, antisense: ACA TCA
GGT TTC CAC GTC TCA CCA; TGF-b1 sense: AAC TAT
TGC TTC AGC TCC ACA GAG; anti-sense: AGT TGG ATG
GTA GCC CTT G; HPRT sense: CTC ATG GAC TGA TTA
TGG ACA GGA C; anti sense =GCA GGT CAG CAA AGA
ACT TAT AGC C. The amount of the target gene was
normalized first to the endogenous reference (HPRT) and then
relative to a calibrator (control animal), using the 22DDCt method
[15]. Steady-state mRNA levels are thus expressed as an n-fold
difference relative to the calibrator. Analyses were performed with
the Sequence Detection Software 1.9 (SDS). Results are expressed
as mean values 6 standard errors with comparisons between
groups performed by analysis of variance (ANOVA).
Primary culture of mouse lung fibroblasts
Mouse lungs were perfused via the right ventricle with 5 ml cold
PBS and removed under aseptic conditions. The left lung was
minced with scissors in DMEM containing 10% FBS and placed
in 10 ml of medium in 10-cm diameter tissue culture plates.
Fibroblasts were allowed to grow out of the minced tissue and
when cells reached 70% confluence, they were passaged following
trypsinization. Fibroblasts were grown for 10–15 days (2–3
passages) before being used. The methodology employed here
was based on the finding of Moore et al, [16] that following 14
days in culture, the cells are uniformly positive for collagen I
protein as evidenced by intracellular flow cytometry analysis and
also express mRNA for collagen I, collagen III and fibronectin. A
different group [17] has used the exact same fibroblast isolation
technique and has described that fibroblasts isolated this way stain
positive for vimentin and negative for keratin, and that by
transmission electron microscopy they have morphology consistent
with that of fibroblasts. Our group has previously done lung
fibroblast purification and culture according to this methodology
[18].
Immunoblot analysis
For collagen I analysis, the cells were plated, serum-starved
overnight, and then treated for 18 h with TGF-b1 (5 ng/ml) alone
or in combination with BMP-7 (300 ng/ml). For phosphorylated
proteins, cells were treated for 15 minutes with the same
concentrations of TGF-b1 and BMP-7. Cells were washed in
PBS and disrupted in lysis buffer (PBS containing 1% Nonidet-
P40, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM orthovana-
date, and Roche protease cocktail inhibitor). Equal amounts of
lysate protein were separated by SDS-PAGE and transferred to
nitrocellulose membranes. Membranes were blocked in 5% nonfat
milk in Tris-buffered solution with 0.1% Tween. They were then
incubated overnight at 4uC with the respective primary antibodies
against collagen I, phospho-p38 MAPK, phospho-Smad2, and
phospho-Smad3 (1:1000 in 2% BSA/0.02% sodium azide in
TBST). Proteins of interest were detected using the ECL enhanced
chemiluminescence method. Densitometry of the bands was
calculated with DigiDoc1000 (AlphaEase FC software, version
3.2 Beta, AlphaInnotech) and normalized for b-actin or the
respective total proteins, which were used as loading controls.
In vivo treatment with rhBMP-7
Mice were anesthetized by an i.p. injection of 100 ml of 5%
xylazine/10% ketamine v/v in sterile PBS. Human recombinant
BMP-7 (300 mg/kg in a total volume of 30 ml) in PBSA isotonic
buffer (140 mM NaCl, 2,7 mM KCl, 8 mM Na2HPO4 and
1.5 mM KH2PO4), was administered intranasally every other day
between days 17 and 30 of the chronic asthma protocol (Figure 2).
Animals in the control groups received the same volume of the
vehicle by the same route and timing. Lungs were processed for
Figure 4. TGF-b and BMP-7 mRNA expression in lung tissue. BMP-7 (A) and TGF-b (B) mRNA in whole lung preparations. The TGF-b/BMP-7
ratio was calculated (C). HPRT was used as housekeeping gene. Data are representative of 5 animals in each of 3 independent experiments. *p,0.05
comparing with control group; D p,0.05 comparing acute with chronic groups. In the insert, collagen-I (area/um2).
doi:10.1371/journal.pone.0095959.g004
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histology, stained with Masson’s trichrome for collagen, and
morphometric analysis was performed as described.
Data analysis
Data are presented as mean values 6SEM of 5 mice per group
in each of 3 independent experiments. Statistical significance was
analyzed using GraphPad Prism 5 (version 5.01; GraphPad
Software). Significance was assessed by ANOVA and a post hoc
Bonferroni test for three or more groups. P,0.05 was considered
significant.
Results
Establishment of the chronic asthma protocols
Balb/c mice were immunized with two i.p. inoculations of
OVA/alum and subjected to six exposures to aerosol of OVA.
One day after the last exposure, they were euthanized and the
lungs processed for evaluation of cell infiltration, mucus, collagen,
and a-SMA. The number of cells in the bronchoalveolar lavage
fluid increased from 18.661.2 in the control to 79.6616.5 in
asthmatic lungs. This increase was due to migration of eosinophils
and neutrophils, which amounted to 70 and 26% of the cells,
respectively.
Mucus production was evaluated in lung histological sections
stained with PSA. As shown in Figure 3A, the morphometric
analysis shows a significantly higher level of mucus in the
asthmatic group, when compared with the control group.
Alpha smooth muscle actin (a-SMA) expression has been
extensively used as a marker of fibroblast differentiation into its
activated state, the myofibroblast. Expression of a-SMA was
followed by thickening of the bronchial muscular wall, increasing
around the bronchi of animals that were exposed to six allergen
challenges, when compared to the control group (Figure 3B).
These results were confirmed by morphometric analysis.
The a-SMA-positive myofibroblasts actively synthesize ECM
components. Initially we measured peribronchial collagen in lung
sections stained with Picrosirius. We found enhanced deposition
around small bronchi in the asthmatic group, when compared to
the control group (data not shown). This staining does not
differentiate between different types of collagen. We then
measured type I collagen, the main collagen isoform produced
by fibroblasts in many fibrotic processes. By immunohistochem-
istry, we found increased type I collagen in the sub-epithelial
region of small bronchi in the asthma group. Morphometric
analysis showed that type I collagen deposition was significantly
higher in the asthma group when compared to the control group
(Figure 3C). Taken together, these results show that this asthma
model proves effective in generation en effector response, where
there is evident lung tissue remodeling with a fibrotic component
around the airways.
The ratio TGF-b1/BMP-7 as a tool to evaluate the
intensity of lung fibrosis
TGF-b1 is the prototypic pro-fibrotic cytokine and its signaling
is inhibited by BMP-7. As expected, TGF-b1 was elevated in the
BALF of asthmatic animals when compared to controls. Treat-
ment with BMP-7 300 mg/kg reduced TGF-b1 levels in the BAL
fluid, showing a further regulatory role of BMP-7, not only over
TGF-b1 signaling but possibly also synthesis or secretion. Levels of
TGF-b1 were 61.1069.432 pg/ml in the controls,
386.3654.3 pg/ml in the asthmatic animals and
200.0613.56 ng/ml in the asthmatic animals treated with BMP-
7. Increased collagen, as seen in Figure 3, correlates with
predominance of TGF-b1 over BMP-7. The mRNA expression
of these molecules, analyzed in homogenates of whole lung,
showed similar levels of TGF-b1 in the acute and chronic asthma
groups, but the expression of BMP-7 was much higher in the acute
asthma group (Figures 4A and B). When the TGF-b1/BMP-7
ratio (Figure 4C) was analyzed, acute asthma correlated with a low
ratio whereas chronic asthma correlated with a higher ratio.
Moreover, there was a direct correlation between the TGF-b1/
BMP-7 ratio and the levels of collagen deposition (see insert of
Figure 4). These results suggest that the TGF-b1/BMP-7 ratio
could be used to predict the intensity of lung fibrosis.
Figure 5. BMP-7 inhibits TGF-b1-induced synthesis of collagen-
I by lung fibroblasts. Mouse lung fibroblasts from control animals (A)
were stimulated with TGF-b1 (5 ng/ml) alone or in combination with
BMP-7 (30, 100 ou 300 ng/ml) during 18 hours. Mouse lung fibroblasts
from asthmatic animals (B) were treated with TGF-b1 (5 ng/ml) alone or
in combination with BMP-7 (300 ng/ml). Type I collagen was analyzed
by western blot and normalized by b-actin expression. Results are
presented as percentage of the control or as arbitrary units. Data are
representative of 5 animals in each of 3 independent experiments. *p,
0.05 comparing with the control group.
doi:10.1371/journal.pone.0095959.g005
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BMP-7 inhibits TGF-b1-induced collagen synthesis by
lung fibroblasts
Fibroblasts were isolated from the lungs of healthy mice and
incubated with TGF-b1 (5 ng/ml) alone or in combination with
BMP-7 (30, 100, and 300 ng/ml). TGF-b1 increased type I
collagen expression, which was reversed, in a dose-dependent
fashion, by co-incubation with BMP-7 (Figure 5A). Similar results
were obtained when fibroblasts were isolated from asthmatic lungs
(data not shown).
To investigate which signaling pathways activated by TGF-b1
are inhibited by BMP-7, we chose the classic Smad-dependent
pathway (Smad 2 and 3) and the Smad-independent pathway, p38
MAPK, since these signaling pathways have been extensively
implicated in fibrosis models and in human diseases involving
fibrotic processes. Figure 6 shows that, in fibroblasts isolated from
chronic asthmatic lungs, TGF-b1 induced the phosphorylation of
Smads 2 and 3 (Figure 6A), which was partially inhibited by BMP-
7. TGF-b1 also increased p-38 phosphorylation (Figure 6B), which
Figure 6. BMP-7 inhibits SMADs phosphorilation in mouse lung fibroblasts from chronic asthmatic mice. Mouse lung fibroblasts were
treated with TGF-b1 (5 ng/ml) alone or in combination with BMP-7 (300 ng/ml). After 15 min, samples were analyses for SMAD 2 and 3 or p-p38
expression. Proteins were analyzed by western blot and normalized by their respective total proteins. Data are representative of 5 animals in each of 3
independent experiments. *p,0.05 comparing with the control group; D p,0.05 comparing TGF-b1-treated with TGF-b1/BMP-7-treated groups.
doi:10.1371/journal.pone.0095959.g006
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was similarly prevented by BMP-7. Similar results were obtained
with fibroblasts isolated from healthy lungs (data not shown). We
believe that these results indicate that in mouse lung fibroblasts, as
described for hepatic cells, BMP-7 is able to at least partially
inhibit TGF-b1 signaling, measured as inhibition of phosphory-
lation of key signaling components such as p-38 and Smads.
Treatment of asthmatic mice with rhBMP-7 inhibits lung
inflammation and collagen deposition
We showed here that BMP-7 inhibits the TGF-b1-induced
collagen production by lung fibroblasts in vitro, correlating
inversely with the degree of collagen deposition in the lung.
Therefore, we sought to investigate whether in vivo administration
of BMP-7 would reduce lung fibrosis. In the chronic asthma
protocol, rhBMP-7 was administered during the fibrogenic phase
of asthma by intranasal instillation of 300 mg/kg in a total volume
of 30 ml of BMP-7 every other day between days 17 and 30. This
treatment markedly reduced collagen deposition around small
bronchi (Figure 7) and also reduced cell infiltration in the airways,
markedly reducing eosinophils and neutrophils in the bronchoal-
veolar lavage fluid (Figure 8). These results show for the first time
that treatment with BMP-7 is able to attenuate airway fibrosis in
the mouse allergic asthma setting.
Discussion
The persistent inflammation induced by an allergen in
sensitized animals is followed by several structural changes in the
tissue, known as airway remodeling. Regeneration of an injured
tissue involves a tuned balance among molecules that promote or
degrade the ECM. Imbalance of this process leads to excessive
deposition of ECM proteins, mainly type I collagen, leading to
fibrosis and reduction of the lung function [19]. The cellular and
Figure 7. Intranasal treatment with BMP-7 reduces collagen-I expression in chronic asthmatic lungs. Lung slides were stained with
Masson’s Trichrome (blue) and the morphometric analysis was performed as described in methods. Control (A), Chronic asthmatic (B), Chronic
asthmatic treated with BMP-7 (300 mg/kg) by intranasal route (C). Morphometric analysis of the stained area (blue)(D). Data are representative of 5
animals in each of 3 independent experiments. Bars = 50 mm. *p,0.05 comparing with the non asthmatic control; D p,0.05 comparing asthmatic
mice treated or not with BMP-7.
doi:10.1371/journal.pone.0095959.g007
Figure 8. Intranasal treatment with BMP-7 reduces cellular infiltrate in the airways of chronic asthmatic lungs. Total cells in BAL were
counted in a hemocytometer. After cytocentrifugation cells were stained with H.E. for determination of eosinophil and neutrophil numbers. Data are
representative of 5 animals in each of 3 independent experiments. *p,0.05 comparing with the non asthmatic control; D p,0.05 comparing
asthmatic mice treated or not with BMP-7.
doi:10.1371/journal.pone.0095959.g008
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molecular mechanisms behind this imbalance are still poorly
understood.
In the present study, we first established a model of chronic
asthma where OVA-immunized mice were given six OVA
challenges, and measured collagen deposition around bronchi
and a-SMA as markers of fibrosis. These parameters, as well as
mucus secretion, were significantly increased in the asthma model.
As occurs in patients, the chronic exposure to allergens leads to
altered remodeling of lung tissue, culminating in airway fibrosis
[20]. One of the important events in the remodeling process is the
TGF-b1-induced activation of fibroblasts into myofibroblasts,
which express a-SMA protein. In the chronic model, we observed
an increase in a-SMA expression around small bronchi, which is
probably related to local differentiation of fibroblasts into
myofibroblasts. In the lungs, the a-SMA-positive cells actively
synthesize ECM components, such as type I collagen, and type I
collagen was found in the sub-bronchial region. Type I collagen is
the main collagen isoform deposited in tissues in many fibrotic
processes [19,21]. To counteract the fibrogenic effect of TGF-b1,
several molecules can inhibit its signaling, among them BMP-7.
Both TGF-b1 and BMP-7 belong to the same cytokine superfam-
ily, though each of these cytokines presents a unique signaling
pathway with different Smads determining opposite effects.
When we compared the expression of these molecules in acute
and chronic protocols of asthma, we found that the gene
expression for BMP-7 is increased in the acute compared with
the chronic group, but the expression of TGF-b1 was similar in
both groups. The ratio between these molecules clearly shows a
predominance of BMP-7 in the acute model, which has less
collagen, and predominance of TGF-b1 in the chronic model,
which shows higher levels of collagen. This is in accordance with
studies that showed increased fibrosis when BMP-7 signaling is
blocked [22]. We propose that the TGF-b1/BMP-7 ratio could be
used as a marker of disease severity in asthma, as has been
proposed for renal chronic fibrosis [23].
It has been reported that the BMP family counteracts TGF-b1-
induced epithelial-to-mesenchymal transition and reverses chronic
renal injury [19]. In human lung fibroblasts, BMP-7 partially
inhibited myofibroblast-like transformation by TGF-b and BMP-4
reduced TGF-b1-induced extracellular matrix protein production
[24]. In our study, mouse lung fibroblasts from control and
asthmatic animals were grown in culture and treated with TGF-b1
alone or in combination with BMP-7. Treatment with BMP-7 was
effective in inhibiting type I collagen synthesis induced by TGF-
b1. The mechanisms exerted by BMP-7 over specific TGF-b1
signaling pathways have not been previously described in mouse
lung fibroblasts. In our study, BMP-7 inhibited the TGF-b1-
induced phosphorylation of Smad-2 and -3 and p-38.
We then investigated the effect of in vivo administration of
rhBMP-7 in collagen deposition in the chronic asthma model.
Mice were treated with a dose of rhBMP-7 (300 mg/kg) every
other day between days 17 and 30. As expected, TGF-b1 was
elevated in the BALF of asthmatic animals when compared to
controls. Treatment with BMP-7 300 mg/kg reduced TGF-b1
levels in the BAL fluid, showing a further regulatory role of BMP-
7, not only over TGF-b1 signaling but possibly also synthesis or
secretion. This is in accordance with a previous work, [25]
showing that BMP-7 is able to abrogate TGF-b1 activity in renal
proximal tubular epithelial cells both by increasing its binding to
the extracellular matrix and by inhibiting its generation in vitro.
The induction phase of allergic response to OVA was not
influenced by BMP-7 treatment. The animals were immunized
and challenged and the treatment with BMP-7 began on the 16th
day after the first immunization (day 17 of the protocol). At this
time, antibodies have been already produced as well as the effector
Th2 lymphocytes. At the point where BMP-7 was administered,
the intranasal antigen induced effector T lymphocytes migration
to the lungs had already happened, with activation leading to the
chronic lung inflammation. This window of treatment was chosen
because, in our model, it corresponds to the fibrogenic phase,
therefore being of therapeutic relevance. Administration of BMP-7
was performed via the intranasal route. This treatment was able to
significantly decrease collagen deposition around small bronchi.
Similarly, in a model of pulmonary fibrosis induced with asbestos,
treatment with BMP-7 decreased the hydroxyproline levels,
counteracting its antagonist Gremlin, whose levels are elevated
in fibrotic lungs [26]. There is data showing that on a model of
hepatic fibrosis, the BMP-7 RNA levels in the liver are the same
whether the animals are treated or not with BMP-7. Also,
treatment with BMP-7 increases the levels of Gremlin, which is an
antagonist that prevents BMP-7’s ligation to its receptor [27].
Despite the different variables that can influence the effect of in
vivo treatment with BMP-7, our work is the first description of the
anti-fibrotic role of BMP-7 in an allergic setting, such as asthma.
We speculate that in asthma, an increase in BMP-7 expression
occurs after the first exposures to the antigen, aiming to protect the
lung from the allergic injury. With persistent exposure to the
antigen, an imbalance between these two molecules ensues, with
prevalence of TGF-b1, leading to fibrosis.
In conclusion, our work sheds light on the balance between
TGF-b1 and BMP-7 in the remodeling process in the lung in a
model of allergic asthma and proposes that the TGF-b1/BMP-7
ratio could be used as a marker of disease severity. Moreover, it
suggests the possibility of interfering with the fibrotic process in
asthma by intranasal instillation of BMP-7.
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